title: Ustekinumab induces rapid clearing of erythrodermic psoriasis after failure of antitumour necrosis factor therapies.
authors.forename: J
authors.initials: J
authors.lastname: Santos-Juanes
authors.forename: P
authors.initials: P
authors.lastname: Coto-Segura
authors.forename: A
authors.initials: A
authors.lastname: Mas-Vidal
authors.forename: C
authors.initials: C
authors.lastname: Galache Osuna
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D003879:Dermatologic Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D011565:Psoriasis / Q000188:drug therapy*; D017211:Treatment Failure; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors; D000069549:Ustekinumab
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D003879:Dermatologic Agents; D014409:Tumor Necrosis Factor-alpha; D000069549:Ustekinumab